159 related articles for article (PubMed ID: 31308554)
21. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
[TBL] [Abstract][Full Text] [Related]
22. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.
Walton RT; Christie KA; Whittaker MN; Kleinstiver BP
Science; 2020 Apr; 368(6488):290-296. PubMed ID: 32217751
[TBL] [Abstract][Full Text] [Related]
23. Genome editing in plants by engineered CRISPR-Cas9 recognizing NG PAM.
Endo M; Mikami M; Endo A; Kaya H; Itoh T; Nishimasu H; Nureki O; Toki S
Nat Plants; 2019 Jan; 5(1):14-17. PubMed ID: 30531939
[TBL] [Abstract][Full Text] [Related]
24. Blackjack mutations improve the on-target activities of increased fidelity variants of SpCas9 with 5'G-extended sgRNAs.
Kulcsár PI; Tálas A; Tóth E; Nyeste A; Ligeti Z; Welker Z; Welker E
Nat Commun; 2020 Mar; 11(1):1223. PubMed ID: 32144253
[TBL] [Abstract][Full Text] [Related]
25. Expanding the CRISPR Toolbox in
Veillet F; Perrot L; Guyon-Debast A; Kermarrec MP; Chauvin L; Chauvin JE; Gallois JL; Mazier M; Nogué F
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033083
[TBL] [Abstract][Full Text] [Related]
26. Targeted mutagenesis in mice via an engineered AsCas12f1 system.
Fan P; Wang H; Zhao F; Zhang T; Li J; Sun X; Yu Y; Xiong H; Lai L; Sui T
Cell Mol Life Sci; 2024 Jan; 81(1):63. PubMed ID: 38280977
[TBL] [Abstract][Full Text] [Related]
27. [Structure-based optimization and design of CRISPR protein xCas9].
Xue D; Zhu H; Du W; Tang H; Huang Q
Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1385-1395. PubMed ID: 33973451
[TBL] [Abstract][Full Text] [Related]
28. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
[TBL] [Abstract][Full Text] [Related]
29. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Hu JH; Miller SM; Geurts MH; Tang W; Chen L; Sun N; Zeina CM; Gao X; Rees HA; Lin Z; Liu DR
Nature; 2018 Apr; 556(7699):57-63. PubMed ID: 29512652
[TBL] [Abstract][Full Text] [Related]
30. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
[TBL] [Abstract][Full Text] [Related]
31. Precise and broad scope genome editing based on high-specificity Cas9 nickases.
Wang Q; Liu J; Janssen JM; Le Bouteiller M; Frock RL; Gonçalves MAFV
Nucleic Acids Res; 2021 Jan; 49(2):1173-1198. PubMed ID: 33398349
[TBL] [Abstract][Full Text] [Related]
32. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
33. New variants of CRISPR RNA-guided genome editing enzymes.
Murovec J; Pirc Ž; Yang B
Plant Biotechnol J; 2017 Aug; 15(8):917-926. PubMed ID: 28371222
[TBL] [Abstract][Full Text] [Related]
34. SpCas9-NG self-targets the sgRNA sequence in plant genome editing.
Qin R; Li J; Liu X; Xu R; Yang J; Wei P
Nat Plants; 2020 Mar; 6(3):197-201. PubMed ID: 32094641
[TBL] [Abstract][Full Text] [Related]
35. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.
Maji B; Gangopadhyay SA; Lee M; Shi M; Wu P; Heler R; Mok B; Lim D; Siriwardena SU; Paul B; Dančík V; Vetere A; Mesleh MF; Marraffini LA; Liu DR; Clemons PA; Wagner BK; Choudhary A
Cell; 2019 May; 177(4):1067-1079.e19. PubMed ID: 31051099
[TBL] [Abstract][Full Text] [Related]
36. Molecular Mechanism of D1135E-Induced Discriminated CRISPR-Cas9 PAM Recognition.
Kang M; Zuo Z; Yin Z; Gu J
J Chem Inf Model; 2022 Jun; 62(12):3057-3066. PubMed ID: 35666156
[TBL] [Abstract][Full Text] [Related]
37. Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
Li F; Hung SSC; Mohd Khalid MKN; Wang JH; Chrysostomou V; Wong VHY; Singh V; Wing K; Tu L; Bender JA; Pébay A; King AE; Cook AL; Wong RCB; Bui BV; Hewitt AW; Liu GS
Hum Gene Ther; 2019 Nov; 30(11):1349-1360. PubMed ID: 31373227
[TBL] [Abstract][Full Text] [Related]
38. Genome editing in animals with minimal PAM CRISPR-Cas9 enzymes.
Vicencio J; Sánchez-Bolaños C; Moreno-Sánchez I; Brena D; Vejnar CE; Kukhtar D; Ruiz-López M; Cots-Ponjoan M; Rubio A; Melero NR; Crespo-Cuadrado J; Carolis C; Pérez-Pulido AJ; Giráldez AJ; Kleinstiver BP; Cerón J; Moreno-Mateos MA
Nat Commun; 2022 May; 13(1):2601. PubMed ID: 35552388
[TBL] [Abstract][Full Text] [Related]
39. FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity.
Cui Z; Tian R; Huang Z; Jin Z; Li L; Liu J; Huang Z; Xie H; Liu D; Mo H; Zhou R; Lang B; Meng B; Weng H; Hu Z
Nat Commun; 2022 Mar; 13(1):1425. PubMed ID: 35301321
[TBL] [Abstract][Full Text] [Related]
40. Generation of genetically modified mice using SpCas9-NG engineered nuclease.
Fujii W; Ito H; Kanke T; Ikeda A; Sugiura K; Naito K
Sci Rep; 2019 Sep; 9(1):12878. PubMed ID: 31501500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
